|
|
|
|
Grannus BioSciences LTD • Privately held biotechnology company incorporated January 2004 under the Companies Acts in Scotland Registration Number SC240992 • Clinical stage novel anti-inflammatory products • Exclusive World Wide License from the University of Glasgow to issued and pending patents • Managed by Pharmetix Corp. of California, U.S.A. • Corporate Counsel, Dundas & Wilson, Glasgow www.grannusbiosciences.com
Grannus 2004-2005 • Grannus BioSciences Limited Announces Appointment of EGeen as CRO • Grannus BioSciences Ltd. Announces Agreement for Preclinical and Clinical Stage Molecules • Grannus receives a SCIS award from Targeting Innovation • Grannus to file IND/CTA for human clinical testing • Grannus receives Business Growth Fund Award from Scottish Enterprise • Grannus receives Notice of Allowance in Australia and China for its patent applications • Grannus appoints Iain McInnes and Robin Stevenson, Royal Infirmary Scotland and Dr. Minnie McMillan, USC School of Medicine to the Scientific Advisory Board
|
TECHNOLOGY The Company's technology platform is based on bio-pharmaceuticals targeting inflammatory or hyperproliferative disorders. Grannus’ lead product is a unique sesquiterpene glycoside, GBL 310, that inhibits MAP kinase and activates caspase 3 to induce apoptosis in keratinocytes. These cells hyperproliferate in a number of conditions such as psoriasis and actinic keratosis or AK. GBL 310 is at the Phase II stage of clinical testing. This means that the product has already been tested in a human clinical trial to demonstrate its safety and tolerability as a topical agent. Grannus plans to test GBL 310 against AK-- a prevalent pre-malignant condition that can progress to squamous cell carcinoma of the skin. If GBL310 is effective against SCC, the Company will also investigate its effectiveness against other cancers for which there is significant unmet clinical need. The Company’s second product offering is thymosin beta 4 sulfoxide (TB4SO), a potent biologic inhibitor of neutrophils. Neutrophils are often the body's first line of defense against attack by pathogens and infectious agents. However, in chronic disease states, neutrophil infiltration can exacerbate inflammation and cause additional tissue damage. Consequently, the resolution of chronic inflammatory diseases through neutrophil inhibition is an important step in the effective management of a large number of disorders such as psoriasis, contact dermatitis, inflammatory bowel disease, emphysema. The Company has two TB4SO derivatives in development. GBL 100 is at the stage of Phase I human testing against dermatologic conditions. GBL 101 is in preclinical development for application to respiratory disease. Grannus' discovery research involves a series of small molecules selected from a botanical extract library based on their potential effect on inflammatory molecules and processes. These compounds were obtained under an agreement with the Strathclyde Institute for Drug Research. They were selected from the extensive library developed by SIDR based on their ability to inhibit certain products and processes involved in inflammation. They will be screened by Grannus for their ability to ameliorate inflammatory processes in preclinical models for human diseases. |
|